Yuko Iwata

Dr. Yuko Iwata


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2018 in Oncotarget
Verified
Journal Article
Open access
PDF file
YIYuko Iwata
Yuko Iwata
YKYoshimi Katayama
Yoshimi Katayama
YOYasushi Okuno
Yasushi Okuno
SWShigeo Wakabayashi
Shigeo Wakabayashi
Novel inhibitor candidates of TRPV2 prevent damage of dystrophic myocytes and ameliorate against dilated cardiomyopathy in a hamster model Novel inhibitor candidates of TRPV2 prevent damage of dystrophic myocytes and ameliorate against dilated cardiomyopathy in a hamster model

19 December 2019 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
YIYuko Iwata
Yuko Iwata
SIShin Ito
Shin Ito
SWShigeo Wakabayashi
Shigeo Wakabayashi
MKMasafumi Kitakaze
Masafumi Kitakaze

Verified
Journal Article
Open access
PDF file
YIYuko Iwata
Yuko Iwata
TMTsuyoshi Matsumura
Tsuyoshi Matsumura
Muscular dystrophy and dilated cardiomyopathy are intractable diseases and their treatment options are very limited. Transient receptor potential cation channel subfamily V, member 2 (TRPV2), is a stretch-sensitive Ca2+-permeable channel that causes sustained intracellular Ca2+ increase in muscular cells, which is a pathophysiological feature of degenerative muscular disease. Recent reports have clarified that TRPV2 is concentrated and activated in the sarcolemma of cardiomyocytes/myocytes during cardiomyopathy/heart failure and muscular dystrophy. Furthermore, these reports showed that inactivation of TRPV2 ameliorates muscle dysgenesis to improve cardiac function and survival prognosis. Although TRPV2 is a potential therapeutic target for cardiomyopathy, there were no TRPV2 inhibitors available until recently. In this review, we introduce our recent findings and discuss the current progress in the development of TRPV2 inhibitors and their therapeutic applications for cardiomyopathy associated with muscular dystrophy.

26 March 2019 in BMC Pulmonary Medicine
Verified
Journal Article
Open access
PDF file
HMHiroaki Masubuchi
Hiroaki Masubuchi
MUManabu Ueno
Manabu Ueno
TMTOSHITAKA MAENO
TOSHITAKA MAENO
KYKoichi Yamaguchi
Koichi Yamaguchi
KHKenichiro Hara
Kenichiro Hara
MKMasahiko Kurabayashi
Masahiko Kurabayashi
Defective phagocytosis in alveolar macrophages is associated with chronic obstructive pulmonary disease (COPD). Transient receptor potential cation channel subfamily V member 2 (TRPV2), a type of nonselective cation channel pertinent to diverse physiological functions, regulates macrophage phagocytosis. However, the role of TRPV2 in COPD remains poorly understood. Here, we explored the role of TRPV2 in the development of COPD. Macrophage TRPV2 expression and phagocytosis function were measured in MH-S cells (a murine alveolar macrophage cell line) and a cigarette smoke exposure mouse model. TRPV2 expression and phagocytosis function were reduced when MH-S cells were exposed to cigarette smoke extract (CSE). TRPV2 knockdown by siRNA decreased phagocytosis in MH-S cells. Consistently, TRPV2 expression was reduced in alveolar macrophages prepared from bronchoalveolar lavage samples of mice which were exposed to cigarette smoke for 2 months. In addition, the alveolar space was progressively enlarged during development in TRPV2 knockout (TRPV2KO) mice. Moreover, exposure to cigarette smoke for 2 months significantly induced alveolar space enlargement in TRPV2KO mice, but not in wild-type (WT) mice. The phagocytic function of alveolar macrophages from TRPV2KO mice was reduced, compared with macrophages from WT mice. TRPV2 expression is profoundly downregulated in alveolar macrophages at early time points of cigarette smoke exposure. Reduced TRPV2-mediated phagocytic function renders the lung susceptible to cigarette smoke-induced alveolar space enlargement. TRPV2 may provide a therapeutic target for COPD induced by cigarette smoke.

2 January 2020 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
YIYuko Iwata
Yuko Iwata
SWShigeo Wakabayashi
Shigeo Wakabayashi
SIShin Ito
Shin Ito
MKMasafumi Kitakaze
Masafumi Kitakaze

Verified
Journal Article
Open access
PDF file
CTChisato Takahashi
Chisato Takahashi
MOMariko Oishi
Mariko Oishi
YIYuko Iwata
Yuko Iwata
KMKeiko Maekawa
Keiko Maekawa
TMTsuyoshi Matsumura
Tsuyoshi Matsumura
Cardiomyopathy is the leading cause of death in patients with muscular dystrophy (MD). Tranilast, a widely used anti-allergic drug, has displayed inhibitory activity against the transient receptor potential cation channel subfamily V member 2 and improved cardiac function in MD patients. To identify urinary biomarkers that assess improved cardiac function after tranilast administration, we performed a urinary metabolomic study focused on oxidative fatty acids. Accompanying the clinical trial of tranilast, urine specimens were collected over 24 weeks from MD patients with advanced heart failure. Urinary levels of tetranor-PGDM (tetranor-prostaglandin D metabolite), a metabolite of prostaglandin D2, significantly decreased 12 weeks after tranilast administration and were correlated with BNP. These results suggest that prostaglandin-mediated inflammation, which increases with the pathological progression of heart failure in MD patients, was attenuated. Urinary prostaglandin E3 (PGE3) levels significantly increased 4 weeks after tranilast administration. There were positive correlations between the urinary levels of PGE3 and 8-hydroxy-2′-deoxyguanosine, an oxidative stress marker. High PGE3 levels may have a protective effect against cardiomyopathy in MD patients with high oxidative stress. Although further validation studies are necessary, urinary tetranor-PGDM and PGE3 levels may help the current understanding of the extent of advanced heart failure in patients with MD after tranilast administration.